Eric van Hooren has been appointed chief development officer at Xenikos BV which is developing compounds to help patients with serious diseases reset their immune systems. He joins from Acerta Pharma BV where he was responsible for the Bruton’s tyrosine kinase inhibitor acalabrutinib. AstraZeneca Plc gained rights to the compound as part of an equity investment in Acerta in late 2015. Mr van Hooren is replacing Edna Venneker, who is leaving Xenikos to pursue another opportunity.
Xenikos BV announced the appointment on 2 November 2016.
Copyright 2016 Evernow Publishing Ltd